Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,988,103
  • Shares Outstanding, K 178,774
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -253 M
  • EBITDA $ -146 M
  • 60-Month Beta 4.90
  • Price/Sales 7.65
  • Price/Cash Flow N/A
  • Price/Book 19.75

Options Overview Details

View History
  • Implied Volatility 77.69% (+0.07%)
  • Historical Volatility 70.81%
  • IV Percentile 57%
  • IV Rank 36.32%
  • IV High 107.55% on 04/21/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 4) 3.47 (6.20%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 20,719
  • Volume Avg (30-Day) 20,868
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 264,420
  • Open Int (30-Day) 283,224
  • Expected Range 52.44 to 59.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 5
  • High Estimate $-0.38
  • Low Estimate $-0.58
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) -62.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.73 +34.46%
on 03/30/26
58.04 -3.33%
on 04/16/26
+9.15 (+19.48%)
since 03/20/26
3-Month
41.73 +34.46%
on 03/30/26
70.16 -20.03%
on 01/26/26
-10.67 (-15.98%)
since 01/20/26
52-Week
39.01 +43.83%
on 04/21/25
104.32 -46.21%
on 10/09/25
+15.66 (+38.71%)
since 04/17/25

Most Recent Stories

More News
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions...

TEM : 56.10 (+0.41%)
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the...

TEM : 56.10 (+0.41%)
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant...

TEM : 56.10 (+0.41%)
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD)...

GILD : 136.52 (-0.81%)
TEM : 56.10 (+0.41%)
Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16....

TEM : 56.10 (+0.41%)
3 ETFs to Buy Now If You Want to Invest Directly in OpenAI

Cathie Wood’s ARK Invest is giving retail investors a rare shot at OpenAI, bringing pre-IPO AI exposure into ARKK, ARKW, and ARKF

ARKW : 138.88 (-0.17%)
$SPX : 7,102.75 (-0.33%)
CRCL : 102.36 (-3.35%)
COIN : 208.68 (+1.14%)
ARKK : 79.04 (-0.24%)
SHOP : 133.96 (+2.14%)
ARKF : 43.53 (-0.09%)
TSLA : 392.78 (-1.96%)
CRSP : 57.74 (-0.43%)
AMD : 273.71 (-1.68%)
XYZ : 73.30 (+2.86%)
TEM : 56.10 (+0.41%)
Bye Bye, AMD! Cathie Wood Ditches 57K Advanced Micro Shares

Cathie Wood offloads AMD along with a bunch of other tech stocks as she moves away from semiconductor.

NVDA : 200.32 (-0.67%)
META : 672.43 (-2.34%)
ROKU : 118.48 (+1.97%)
CRCL : 102.36 (-3.35%)
AMD : 273.71 (-1.68%)
$IUXX : 26,562.58 (-0.41%)
TEM : 56.10 (+0.41%)
TSM : 368.07 (-0.66%)
Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease...

TEM : 56.10 (+0.41%)
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit...

TEM : 56.10 (+0.41%)
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology...

TEM : 56.10 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 60.03
2nd Resistance Point 58.80
1st Resistance Point 57.33
Last Price 56.10
1st Support Level 54.64
2nd Support Level 53.41
3rd Support Level 51.94

See More

52-Week High 104.32
Fibonacci 61.8% 79.37
Fibonacci 50% 71.67
Fibonacci 38.2% 63.96
Last Price 56.10
52-Week Low 39.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.